Foamix Pharmaceuticals (FOMX) and Its Rivals Head-To-Head Analysis

Foamix Pharmaceuticals (NASDAQ: FOMX) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Foamix Pharmaceuticals to related companies based on the strength of its analyst recommendations, profitability, valuation, risk, institutional ownership, earnings and dividends.

Analyst Ratings

This is a summary of current ratings and recommmendations for Foamix Pharmaceuticals and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foamix Pharmaceuticals 0 0 3 0 3.00
Foamix Pharmaceuticals Competitors 848 3199 11594 230 2.71

Foamix Pharmaceuticals currently has a consensus price target of $9.67, indicating a potential upside of 69.29%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 47.01%. Given Foamix Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Foamix Pharmaceuticals is more favorable than its competitors.

Earnings & Valuation

This table compares Foamix Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Foamix Pharmaceuticals $5.53 million -$29.33 million -3.55
Foamix Pharmaceuticals Competitors $284.28 million $34.29 million 133.63

Foamix Pharmaceuticals’ competitors have higher revenue and earnings than Foamix Pharmaceuticals. Foamix Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Foamix Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Foamix Pharmaceuticals -1,439.32% -54.81% -50.94%
Foamix Pharmaceuticals Competitors -5,302.63% -356.16% -38.98%

Volatility and Risk

Foamix Pharmaceuticals has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Foamix Pharmaceuticals’ competitors have a beta of 5.86, suggesting that their average stock price is 486% more volatile than the S&P 500.

Insider and Institutional Ownership

57.4% of Foamix Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply